| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 2,061 | 7,196 | 17,152 | NaN |
| Total research and development | 21,527 | 24,476 | 87,736 | NaN |
| General and administrative | 9,465 | 14,027 | 10,398 | NaN |
| Other | -1,967 | -2,228 | -3,063 | NaN |
| Net loss | -26,964 | -29,079 | -13,448 | -23,256 |
| Depreciation and amortization | 658 | 682 | 763 | 1,580 |
| Share-based compensation expense | 4,325 | 6,817 | 5,729 | 12,862 |
| Gain on sale of equipment | 34 | NaN | NaN | NaN |
| Foreign currency transaction loss | -1 | -63 | -170 | -149 |
| Impairment of right-of-use assets | NaN | 1,897 | NaN | NaN |
| Accounts receivable | -4,221 | -2,387 | -9,253 | 13,230 |
| Prepaid expense and other assets | -809 | -916 | 57 | -4,145 |
| Right-of-use assets | -658 | -861 | -955 | -1,880 |
| Accounts payable | -142 | -1,343 | -5,045 | 3,429 |
| Accrued liabilities | -1,233 | 4,453 | -5,417 | -14,301 |
| Deferred revenue | -636 | -2,800 | -8,986 | -12,086 |
| Lease liabilities | -1,104 | -1,081 | -1,068 | -2,065 |
| Net cash used in operating activities | -19,441 | -16,227 | -17,151 | -40,893 |
| Acquisition of property and equipment | 0 | -88 | 181 | 137 |
| Proceeds from sale of equipment | 34 | NaN | NaN | NaN |
| Proceeds from issuance of common stock under equity plans | NaN | 0 | 585 | NaN |
| Net cash used in investing activities | 34 | 88 | -181 | -137 |
| Proceeds from issuance of common stock, net of issuance costs | NaN | 11,688 | NaN | NaN |
| Payments on debt obligations | NaN | 0 | 0 | 15,000 |
| Proceeds from exercise of stock options | 16 | 0 | 640 | 469 |
| Proceeds from debt | 0 | 0 | 0 | 15,000 |
| Net cash provided by financing activities | 16 | 11,688 | 1,225 | 469 |
| Net decrease in cash, cash equivalents and restricted cash | -19,391 | -4,451 | -16,107 | -40,561 |
| Cash, cash equivalents and restricted cash at beginning of the period | 232,794 | 237,245 | 293,913 | NaN |
| Cash, cash equivalents and restricted cash at end of the period | 213,403 | 232,794 | 237,245 | NaN |
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)